NCT05907668View on ClinicalTrials.gov

A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Graves Disease
Interventions
DRUG

IMVT-1401 (batoclimab)

Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody.

Trial Locations (1)

55131

Site Number - 6505, Mainz

Sponsors
All Listed Sponsors
lead

Immunovant Sciences GmbH

INDUSTRY

NCT05907668 - A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease | Biotech Hunter | Biotech Hunter